SWISF - New to The Street Announces its Five Business Guest Interviews Episode 533 Airs on the FOX Business Network on Monday November 27 2023 at 10:30 PM PT | Benzinga
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its feature lineup for its business show airing on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT.
New to The Street's TV episode 533 will air the following five (5) business interviews:
1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
2). Business Capital Firm - Coastal Kapital, LLC's interview with Kortney Murray, CEO/Founder.
3). ETF Fund - American Conservative Values ETF's (NYSE:ACVF) () interview with Bill Flaig, CEO/Founder.
4). Pet Health - PetVivo Holdings, Inc.'s (NASDAQ:PETV) (NASDAQ:PETVW) () interview with John Lai, CEO/President.
5). "Sekur Privacy & Sekur Security – Weekly Hack Segment" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX:SWISF) (CSE:SKUR) (FRA: GDT0) (Sekur®).
Episode 533
From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ:ACXP) (). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 96% success with no reinfections. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high. ACXP's Ibezapolsat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. David explains how the Company will fund its FDA Phase 3 study and, upon successful approval, will leverage data/results for future approval(s) with the European Medicines Agency. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. The on-screen QR code is available during the show; download or visit Acurx Pharmaceticals, Inc. - https://www.acurxpharma.com/.
From the New York Stock Exchange Studio, New to The Street's TV Host Jane King is with Kortney Murray, CEO/Founder of Coastal Kapital, LLC ("Coastal"), a non-bank and non-credit report funding entity. Capital is the lifeblood of any business, but many small to mid-size companies cannot secure a capital line for their operational needs. Kortney started Coastal Kapital in 2007 to help many secure needed operational funds. Coastal changed the narrative on funding with Kortney and her team looking beyond a person's credit score. They examine the business operations and products/services and perform due diligence to understand business owners' commitment and sacrifices. Kortney says that current bank loan algorithms have been in place since the 1950s, and they only look at credit scores as the mathematical stats to approve loans. Coastal differentiates itself by looking at the human element behind an operation and seeks to understand the business owners' needs and how funding can grow existing operations. Coastal Kapital is raising money through a "Private Placement Memorandum" under the US SEC Rule 506(c) of Regulation D. Funds raised will increase the capital pool Coastal can use to assist those in need. The money raised will help women, minorities, and other businesses in their operations. Education is key to financial literacy, and Coastal looks to establish online resources and other collaborations to help people understand finance terminologies and methodologies. With current interest rates, Korney assists many manufacturers and vendors with difficulties securing necessary equipment and provides sales training and marketing ideas to grow product sales/services during these economic times. Throughout 2024, Kortney believes its debt funding will be in place so Coastal Kapital can expand its reach and help as many as possible secure business capital needs. Coastal Kapital, LLC continues to grow regardless of current macroeconomic conditions, and its services are available nationwide – "Financing You Can Trust." The on-screen QR code is available during the show; download or visit Coastal Kapital, LLC - https://coastalkapital.com/.
American Conservative Values ETF's (NYSE:ACVF) Bill Flaig, Founder/CEO, and New to The Street's Jane King are at the New York Stock Exchange Studio talking about the Fund's conservative investment criteria. The Fund looks for investments in conservative-run companies seeking growth for its politically conservative investors. Bill explains that many investors don't realize that their 401(k) and other investment instruments have financial positions in public companies whose management teams are more involved with political ideologies than running a business effectively. Management with political agendas hurt shareholder returns and tarnish the brands of goods and services produced. Unknowingly, an investor's money might be within investment funds with companies who restrict and promote negativity on conservative attitudes, promoting it on social media platforms, reducing banking access, ...